Literature DB >> 5451592

Monoamine oxidase inhibitors and L-dopa.

K R Hunter, A J Boakes, D R Laurence, G M Stern.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5451592      PMCID： PMC1701271          DOI： 10.1136/bmj.3.5719.388

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  7 in total

1.  MONOAMINE-OXIDASE INHIBITORS, BROAD BEANS, AND HYPERTENSION.

Authors:  J V HODGE; E R NYE; G W EMERSON
Journal:  Lancet       Date:  1964-05-16       Impact factor: 79.321

2.  [On the effects of L-dopa in man and their modification by reserpine, chlorpromazine, iproniazid and vitamin B6].

Authors:  R DEGKWITZ; R FROWEIN; C KULENKAMPFF; U MOHS
Journal:  Klin Wochenschr       Date:  1960-02-01

3.  Effects of Dopamine in man.

Authors:  D HORWITZ; 3 D FOX SM; L I GOLDBERG
Journal:  Circ Res       Date:  1962-02       Impact factor: 17.367

4.  Case of self-poisoning with multiple antidepressant drugs.

Authors:  A V Simmons; D Carr; E J Ross
Journal:  Lancet       Date:  1970-01-31       Impact factor: 79.321

5.  Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure.

Authors:  J Elis; D R Laurence; H Mattie; B N Prichard
Journal:  Br Med J       Date:  1967-04-08

Review 6.  Psychotropic drugs (2). Interaction between monoamine oxidase (MAO) inhibitors and other substances.

Authors:  F Sjöqvist
Journal:  Proc R Soc Med       Date:  1965-11

7.  Dopamine (3-hydroxytyramine) metabolism in parkinsonism.

Authors:  M Goodall; H Alton
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808
  7 in total
  19 in total

1.  Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.

Authors:  J P M Finberg; A Gross; O Bar-Am; R Friedman; Y Loboda; M B H Youdim
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

2.  Drug interactions with antihypertensive drugs.

Authors:  J E Crook; A S Nies
Journal:  Drugs       Date:  1978-01       Impact factor: 9.546

Review 3.  Banisteriopsis caapi, a Forgotten Potential Therapy for Parkinson's Disease?

Authors:  Atbin Djamshidian; Sabine Bernschneider-Reif; Werner Poewe; Andrew J Lees
Journal:  Mov Disord Clin Pract       Date:  2015-10-06

Review 4.  Augmenting the action of levodopa.

Authors:  S K Rao; S D Vakil; D B Calne; A Hilson
Journal:  Postgrad Med J       Date:  1972-11       Impact factor: 2.401

Review 5.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

Review 6.  Antiparkinsonian drugs: pharmacological and therapeutic aspects.

Authors:  D B Calne; J L Reid
Journal:  Drugs       Date:  1972       Impact factor: 9.546

7.  Amyloidosis complicated by intractable postural hypotension.

Authors:  G M Yuill
Journal:  Postgrad Med J       Date:  1973-01       Impact factor: 2.401

Review 8.  Parkinson's disease in 1984: an update.

Authors:  A E Lang; R D Blair
Journal:  Can Med Assoc J       Date:  1984-11-01       Impact factor: 8.262

9.  Idiopathic orthostatic hypotension treated with levodopa and MAO inhibitor: a preliminary report.

Authors:  J Sharpe; A Marquez-Julio; P Ashby
Journal:  Can Med Assoc J       Date:  1972-08-19       Impact factor: 8.262

10.  Interactions between sympathomimetic amines and antidepressant agents in man.

Authors:  A J Boakes; D R Laurence; P C Teoh; F S Barar; L T Benedikter; B N Prichard
Journal:  Br Med J       Date:  1973-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.